Conflict of Interest
NMS, Cancer
EMD, NMS, ONCOLOGY, EDWARDS, CANCER
Josep Tabernero Array Biopharma, AstraZeneca, Avvinity, Bayer, Boehringer Ingelheim, Chugai, Daiichi Sankyo, F. Hoffmann-La Roche Ltd, Genentech Inc., HalioDX SAS, Hutchison MediPharma International, Ikena Oncology, IQVIA, Lilly, Menarini, Merck Serono, Merus, MSD, Mirati, NeoPhore, Novartis, Ona Therapeutics, Orion Biotechnology, Peptomyc, Pfizer, Pierre Fabre, Samsung Bioepis, Sanofi, Seattle Genetics, Scandion Oncology, Servier, Taiho, Tessa Therapeutics, and TheraMyc (consulting/advisory); Imedex, Medscape Education, MJH Life Sciences, PeerView Institute for Medical Education, and Physicians Education Resource (PER) (educational collaboration); Amgen Inc., Array Biopharma Inc., AstraZeneca Pharmaceuticals LP, BeiGene, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Debiopharm International SA, F. Hoffmann-La Roche Ltd, Genentech Inc., HalioDX SAS, Hutchison MediPharma International, Janssen-Cilag SA, MedImmune, Menarini, Merck Health KGAA, Merck Sharp & Dohme, Merus NV, Mirati, Novartis Farmacéutica SA, Pfizer, Pharma Mar, Sanofi Aventis Recherche & Développement, Servier, Taiho Pharma USA Inc., Spanish Association Against Cancer Scientific Foundation, and Cancer Research UK (research funding). Eric Van Cutsem Array, AstraZeneca, Bayer, Biocartis, Bristol Myers Squibb, Celgene, Eli Lilly, Ipsen, MSD, Merck KGaA, Novartis, Pierre Fabre, Roche, Servier, Sirtex, and Taiho (consulting/advisory); Amgen, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Ipsen, Merck, Merck KGaA, Novartis, Roche, and Servier (research funding). Elena Garralda Alkermes, Anaveon, Boehringer, Bristol Myers Squibb, F. Hoffman/La Roche, Ingelheim, Janssen Global Services, MabDiscovery, Roche/Genentech, Seattle Genetics, TFS, and Thermo Fisher (consulting/advisory); AstraZeneca, BeiGene, Novartis, Roche, Taiho, and Thermo Fisher (research funding). David Tai F. Hoffman/La Roche. Filippo De Braud AstraZeneca, EMD Serono, Incyte, Menarini, MSD, NMS Nerviano Medical Science, Novartis, Roche, and Sanofi (consulting/advisory). Ravit Geva AstraZeneca, Bayer, Boehringer Ingelheim, BOL Pharma, EISAI, MSD, Novartis, and Roche (consulting/advisory); Bristol Myers Squibb, Janssen, Lilly, Medison, Merck, MSD, Novartis, Pfizer, Roche, and Takeda (honoraria); Novartis (research funding); Bayer, Bristol Myers Squibb, Medison, Merck, BOL Pharma, and Pyxis (travel, accommodations and/or expenses). Mark T.J. van Bussel reported no financial relationships. Katia Fiorella Dotti reported no financial relationships. Elena Elez Amgen, Array BioPharma, Bayer, Merck Serono, MSD, Pierre Fabre, Roche, Sanofi, and Servier (consulting/advisory). María J. de Miguel MSD, PharmaMar, Roche, Novartis, AbbVie, Array, Eisai, Faron, and Sanofi (research funding); MSD, Janssen, Roche (speakers’ bureau). Kevin Litwiler Volestra (consultant/advisory role); Pfizer (employee); OnKure Therapeutics (employee, leadership role, stockholder). Danielle Murphy Pfizer (employee, ownership interests). Michelle Edwards Pfizer (former employee and stockholder); Arvinia (employee and stockholder). Van Karlyle Morris Array, Axiom Healthcare Strategies, Bayer, Bicara Therapeutics, BioMedical Insights, Boehringer Ingelheim, Incyte, Pfizer, and Servier (consulting/advisory); BioNTech AG, Boehringer Ingelheim, Bristol Myers Squibb, EMD Serono, Immatics, Novartis, and Pfizer (research funding).